AC Immune SA (ACIU) vs Akebia Therapeutics (AKBA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AC Immune SA (ACIU) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 28.4% versus a loss of 70.4%. Over five years, ACIU leads with a -58.4% price change compared with -69.4% for AKBA. AC Immune SA is the larger company by market cap ($253.5 million vs $225.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | AKBA |
|---|---|---|
| Share price | $2.55 | $0.8148 |
| Market cap | $253.54M | $225.79M |
| 1-day change | -0.78% | -6.71% |
| YTD return | -18.15% | -45.75% |
| 1-year return | -28.41% | -70.39% |
| 5-year return | -58.41% | -69.35% |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $3.20 |
| 52-week low | $2.10 | $0.814 |
| Distance from 52-week high | -36.25% | -74.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +234.12% | +381.10% |
| Average volume | 202.76K | 6.13M |
| Shares outstanding | 99.43M | 277.11M |
| Employees | 90 | 194 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed AKBA by 42.0 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
ACIU vs AKBA FAQ
Which is bigger, AC Immune SA or Akebia Therapeutics?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $225.79M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, ACIU or AKBA?
ACIU returned -28.41% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Akebia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.